Fonte: Annals of hepatology. Unidade: FM
Assuntos: HEPATITE C, HEPATITE CRÔNICA, CIRROSE HEPÁTICA, ANTIRRETROVIRAIS, ANTIVIRAIS, QUIMIOTERAPIA COMBINADA
ABNT
PESSOA, Mario G et al. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis. Annals of hepatology, v. 17, n. 6, p. 959-968, 2018Tradução . . Disponível em: https://doi.org/10.5604/01.3001.0012.2244. Acesso em: 19 nov. 2024.APA
Pessoa, M. G., Ramalho-Madruga, J. V., Alves, K., Nunes, E. P., Cheinquer, H., Brandão-Mello, C. E., et al. (2018). Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis. Annals of hepatology, 17( 6), 959-968. doi:10.5604/01.3001.0012.2244NLM
Pessoa MG, Ramalho-Madruga JV, Alves K, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Correa MC, Ferraz ML, Ferreira PRA, Alvares-da-Silva MR. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis [Internet]. Annals of hepatology. 2018 ; 17( 6): 959-968.[citado 2024 nov. 19 ] Available from: https://doi.org/10.5604/01.3001.0012.2244Vancouver
Pessoa MG, Ramalho-Madruga JV, Alves K, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Correa MC, Ferraz ML, Ferreira PRA, Alvares-da-Silva MR. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis [Internet]. Annals of hepatology. 2018 ; 17( 6): 959-968.[citado 2024 nov. 19 ] Available from: https://doi.org/10.5604/01.3001.0012.2244